Evidence map›Paper›PMID 19857081›Full record

Trial reportJournal of medicinal food2009

The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis.

Sarah L Morgan, Joseph E Baggott, Larry Moreland, Renee Desmond, Angela C Kendrach

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medicinal food, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00294125 (Flavocoxid), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00294125 phase1completednot on this map

Flavocoxid: A Medical Food Therapy for Osteoarthritis

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2006 to 2007Enrolled59ConditionsOsteoarthritisArmsFlavocoxid, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah L MorganDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama 35294-1270, USA. slmorgan@uab.edu
Joseph E Baggott
Larry Moreland
Renee Desmond
Angela C Kendrach
University of Alabama at Birmingham · USUniversity of Pittsburgh · US

Funding

Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6M
Flavocoxid: A Medical Food Therapy for OsteoarthritisR41AR051232 · NIAMS · PRIMUS PHARMACEUTICALS, INC. · PI MORGAN, SARAH LUISE · 2004 to 2004
$210k
NCRR NIH HHS M01 RR-00032NIAMS NIH HHS R41 AR051232
6 · The paper itself

Abstract

This study was designed to determine the safety of a medical food, flavocoxid, a proprietary blend of free-B ring flavonoids and flavans from the root of Scutellaria baicalensis (Chinese skullcap) and the bark of Acacia catechu in the dietary management of knee osteoarthritis. The 12-week, randomized, double-blind, placebo-controlled trial in an academic medical center enrolled 59 patients with moderate osteoarthritis of at least one knee who were recruited who were classified as having "below average" to "a moderately above average cardiovascular risk" with a Framingham-based scoring tool. Subjects were randomized to flavocoxid 250 mg twice a day versus identical placebo. Safety measures, including recording of adverse events, incidence of serious adverse events, and results of routine laboratory values, were compared between the two groups. There were no major differences in the baseline demographic characteristics of the placebo and flavocoxid groups. With one exception no significant differences were found between the two groups with respect to adverse events by body system, blood pressure, or laboratory values. There was a significantly higher incidence of upper respiratory adverse events in the placebo group (35.4% vs. 5.8%, P = .0003). There were no intra- or inter-group differences in any of the laboratory parameters from study baseline to completion. Thus, flavocoxid is safe when used in a population with "below average" to "moderately above average cardiovascular risk" compared to placebo.

Indexed as

AcaciaAgedDouble-Blind MethodFemaleFlavonoidsHumansKnee JointMaleMiddle AgedOsteoarthritis, KneePlant BarkPlant ExtractsPlant RootsScutellaria baicalensisFlavonoidsPlant Extracts

Identifiers

PMID19857081
PMCPMC2784890
OpenAlexW1998551599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.